
  
    
      
        Introduction_NNP
        The_DT precise_JJ role_NN played_VBN by_IN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN the_DT
        pathogenesis_NNS and_CC inflammation_NN of_IN rheumatoid_NN arthritis_NN (_( RA_NNP )_)
        is_VBZ unclear_JJ ._. In_IN the_DT synovial_NN membrane_NN ,_, the_DT most_RBS common_JJ
        IFN-γ-producing_NNP cell_NN is_VBZ the_DT CD_NNP 8_CD +_NN T_NN cell_NN ,_, suggesting_VBG that_IN
        this_DT population_NN of_IN T_NN cells_NNS plays_VBZ a_DT major_JJ role_NN in_IN macrophage_NN
        activation_NN and_CC perpetuation_NN of_IN the_DT inflammatory_JJ response_NN [_NN
        1_CD ]_NN ._. CD_NNP 8_CD +_NN T_NN cells_NNS were_VBD recently_RB associated_VBN with_IN the_DT
        presence_NN of_IN germinal_NN centers_NNS in_IN RA_NNP synovium_NN [_NN 2_CD ]_NN ,_,
        suggesting_VBG a_DT role_NN for_IN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN the_DT formation_NN or_CC
        maintenance_NN of_IN those_DT lymphoid_NN structures_NNS in_IN the_DT synovium_NN ._.
        Further_RB studies_VBZ indicated_VBD that_IN CD_NNP 8_CD +_NN T_NN cells_NNS exhibit_NN
        oligoclonality_NN in_IN the_DT peripheral_JJ blood_NN [_NN 3_CD 4_CD ]_NN and_CC synovial_NN
        fluid_NN of_IN RA_NNP patients_NNS [_NN 5_CD ]_NN ,_, raising_VBG the_DT question_NN of_IN
        whether_IN this_DT oligoclonality_NN is_VBZ antigen_NN driven_VBN ._. However_RB ,_,
        recent_JJ studies_NNS have_VBP indicated_VBN that_IN large_JJ numbers_NNS of_IN
        virus-specific_JJ CD_NNP 8_CD +_NN T_NN cells_NNS preferentially_RB accumulate_VBP in_IN
        the_DT synovial_NN fluid_NN of_IN RA_NNP patients_NNS and_CC that_IN these_DT cells_NNS are_VBP
        also_RB oligoclonal_NN ,_, suggesting_VBG that_IN non-antigen-specific_JJ
        homing_VBG may_MD be_VB responsible_JJ for_IN the_DT observed_VBN oligoclonality_NN
        of_IN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN the_DT synovial_NN fluid_JJ [_NN 6_CD ]_NN ._. Because_IN
        chemokines_NNS such_JJ as_IN macrophage_NN inflammatory_JJ protein-_NN 1_CD α_NN and_CC
        RANTES_NNP (_( regulated_VBN upon_IN activation_NN ,_, normal_JJ T-_NNP cell_NN expressed_VBD
        and_CC secreted_JJ )_) are_VBP expressed_VBN in_IN RA_NNP synovial_NN tissue_NN [_NN 7_CD 8_CD ]_NN ,_,
        subsets_NNS of_IN CD_NNP 8_CD +_NN T_NN cells_NNS may_MD be_VB preferentially_RB recruited_VBN
        into_IN the_DT synovial_NN tissue_NN in_IN a_DT non-antigen-specific_JJ manner_NN ._.
        If_IN the_DT expression_NN of_IN chemokines_NNS is_VBZ also_RB accompanied_VBN by_IN a_DT
        perturbation_NN in_IN CD_NNP 8_CD +_NN T-_NNP cell_NN homeostasis_NNS in_IN the_DT periphery_NN
        that_WDT favors_VBZ differentiation_NN into_IN cell_NN types_NNS that_WDT can_MD be_VB
        recruited_VBN into_IN the_DT synovium_NN ,_, then_RB a_DT vicious_JJ cycle_NN may_MD be_VB
        set_VBN up_RP in_IN RA_NNP in_IN which_WDT there_EX is_VBZ continuous_JJ generation_NN of_IN CD_NNP 8_CD
        +_NN T_NN cells_NNS that_WDT can_MD be_VB recruited_VBN into_IN the_DT synovium_NN ,_, resulting_VBG
        in_IN chronic_JJ inflammation_NN and_CC joint_JJ destruction_NN ._.
        Recently_RB ,_, memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS were_VBD classified_VBN into_IN three_CD
        distinct_JJ populations_NNS ,_, based_VBN on_IN phenotype_NN [_NN 9_CD 10_CD 11_CD ]_NN :_: a_DT
        central_JJ memory_NN population_NN ,_, which_WDT is_VBZ CD_NNP 45_CD RA_NNP -_: CCR_NNP 7_CD +_NN CD_NNP 62_CD L_NNP
        +_NN CD_NNP 28_CD +_NN IL-_NNP 2_CD +_NN IFN-γ_NNP -_: ;_: and_CC two_CD effector_NN memory_NN populations_NNS ,_,
        namely_RB the_DT CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP -_: CCR_NNP 7_CD -_: and_CC the_DT terminally_RB
        differentiated_JJ CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: CCR_NNP 7_CD -_: populations_NNS ._. The_DT two_CD
        latter_JJ effector_NN memory_NN populations_NNS contain_VBP perforin_NN ,_,
        secrete_NN IFN-γ_NNP and_CC tumor_NN necrosis_NNS factor-α_JJ ,_, are_VBP cytotoxic_JJ ,_,
        and_CC are_VBP capable_JJ of_IN rapid_JJ effector_NN function_NN after_IN
        stimulation_NN [_NN 9_CD 10_CD 11_CD ]_NN ._.
        Although_IN a_DT linear_JJ model_NN of_IN differentiation_NN has_VBZ been_VBN
        suggested_VBN for_IN these_DT memory_NN populations_NNS (_( i_NNP ._. e_SYM ._. central_JJ memory_NN
        T_NN cells_NNS CD_NNP 45_CD RA_NNP -_: CCR_NNP 7_CD +_NN CD_NNP 62_CD L_NNP +_NN →_NN effector_NN memory_NN T_NN cells_NNS
        CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP -_: CCR_NNP 7_CD -_: →_NN effector_NN memory_NN T_NN cells_NNS CD_NNP 45_CD RA_NNP
        +_NN CD_NNP 62_CD L_NNP -_: CCR_NNP 7_CD -_: [_NN 10_CD ]_NN )_) ,_, the_DT exact_JJ relationship_NN between_IN
        these_DT populations_NNS is_VBZ not_RB fully_RB established_VBN ._. Indeed_RB ,_,
        Champagne_NNP 
        et_CC al_NN ._. [_NN 12_CD ]_NN suggested_VBD that_IN the_DT
        differentiation_NN may_MD not_RB be_VB linear_JJ at_IN all_DT ._. The_DT central_NN and_CC
        effector_NN memory_NN phenotypes_NNS of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS in_IN
        peripheral_JJ blood_NN of_IN RA_NNP patients_NNS are_VBP unknown_JJ ._. Determination_NNP
        of_IN these_DT phenotypes_NNS in_IN RA_NNP may_MD provide_VB important_JJ insights_NNS
        into_IN T-_NNP cell_NN homeostasis_NNS ,_, and_CC we_PRP therefore_RB examined_VBD the_DT
        distribution_NN of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS into_IN these_DT
        subpopulations_NNS because_IN such_JJ a_DT study_NN may_MD reveal_VB differences_NNS
        in_IN the_DT differentiation_NN of_IN T_NN cells_NNS in_IN RA_NNP patients_NNS ._. Decreases_NNP
        in_IN some_DT of_IN the_DT subpopulations_NNS in_IN peripheral_JJ blood_NN may_MD
        indicate_VB that_IN there_EX is_VBZ a_DT selective_JJ migration_NN of_IN these_DT cells_NNS
        out_IN of_IN the_DT peripheral_JJ blood_NN ,_, decreased_VBD survival_NN of_IN these_DT
        cells_NNS ,_, or_CC blockade_NN in_IN their_PRP$ differentiation_NN ._. Perturbations_NNP
        in_IN the_DT homeostasis_NNS of_IN memory_NN T_NN cells_NNS may_MD play_VB an_DT important_JJ
        role_NN in_IN the_DT pathogenesis_NNS of_IN RA_NNP by_IN generating_VBG effector_NN cells_NNS
        that_WDT can_MD contribute_VB to_TO the_DT synovial_NN inflammation_NN of_IN RA_NNP ._.
      
      
        Patients_NNS and_CC methods_NNS
        
          Patients_NNS
          Peripheral_NNP blood_NN was_VBD obtained_VBN from_IN patients_NNS with_IN RA_NNP ,_,
          systemic_JJ lupus_JJ erythematosus_JJ (_( SLE_NNP )_) ,_, and_CC healthy_JJ control_NN
          individuals_NNS following_VBG Drexel_NNP University_NNP Institutional_NNP
          Review_NNP Board_NNP approval_NN and_CC obtaining_VBG informed_VBN consent_NN ._. The_DT
          RA_NNP group_NN consisted_VBD of_IN eight_CD patients_NNS (_( seven_CD women_NNS ,_, one_CD
          man_NN )_) with_IN an_DT age_NN range_NN of_IN 33_CD -_: 63_CD years_NNS (_( mean_VB 49_CD years_NNS )_) ._.
          All_DT patients_NNS in_IN the_DT group_NN were_VBD receiving_VBG
          disease-modifying_JJ antirheumatic_JJ drugs_NNS and_CC were_VBD clinically_RB
          stable_JJ ._. The_DT SLE_NNP group_NN consisted_VBD of_IN 12_CD women_NNS with_IN an_DT age_NN
          range_NN of_IN 22_CD -_: 68_CD years_NNS (_( mean_VB 45_CD years_NNS )_) who_WP were_VBD clinically_RB
          stable_JJ ._. All_DT patients_NNS in_IN the_DT two_CD groups_NNS met_VBD the_DT American_NNP
          College_NNP of_IN Rheumatology_NNP criteria_NNS for_IN SLE_NNP and_CC RA_NNP ,_,
          respectively_RB ._. Patient_NNP profiles_NNS and_CC characteristics_NNS are_VBP
          shown_VBN in_IN Table_NNP 1_CD ._. Age-_NNP and_CC sex-matched_JJ healthy_JJ control_NN
          groups_NNS were_VBD included_VBN for_IN the_DT RA_NNP and_CC the_DT SLE_NNP patient_NN
          groups_NNS (_( control_NN group_NN for_IN RA_NNP :_: 
          n_NN =_SYM 8_CD ,_, age_NN range_NN 32_CD -_: 61_CD years_NNS [_NN mean_NN
          50_CD years_NNS ]_NN ;_: and_CC control_NN group_NN for_IN SLE_NNP :_: 
          n_NN =_SYM 12_CD ,_, age_NN range_NN 22_CD -_: 61_CD years_NNS [_NN mean_NN
          46_CD years_NNS ]_NN )_) ._. No_DT statistically_RB significant_JJ difference_NN was_VBD
          found_VBN between_IN the_DT age_NN of_IN the_DT RA_NNP patient_NN group_NN and_CC the_DT
          corresponding_JJ healthy_JJ control_NN group_NN (_( 
          P_NN >_NN 0_CD ._. 9_CD ,_, by_IN Student_NNP 's_POS 
          t_NN -_: test_NN )_) ,_, between_IN the_DT age_NN of_IN the_DT
          SLE_NNP patient_NN group_NN and_CC the_DT corresponding_JJ healthy_JJ control_NN
          group_NN (_( 
          P_NN >_NN 0_CD ._. 9_CD ,_, by_IN Student_NNP 's_POS 
          t_NN -_: test_NN )_) ,_, and_CC between_IN the_DT RA_NNP
          patient_NN group_NN and_CC the_DT SLE_NNP patient_NN group_NN (_( 
          P_NN >_NN 0_CD ._. 5_CD ,_, by_IN Student_NNP 's_POS 
          t_NN -_: test_NN )_) ._.
        
        
          Flow_NNP cytometry_NN
          Heparinized_NNP venous_JJ blood_NN from_IN RA_NNP patients_NNS ,_, SLE_NNP
          patients_NNS and_CC healthy_JJ control_NN individuals_NNS was_VBD collected_VBN ,_,
          and_CC peripheral_JJ blood_NN mononuclear_NN cells_NNS were_VBD freshly_RB
          isolated_VBN by_IN Ficoll-_NNP Hypaque_NNP (_( Amersham_NNP Pharmacia_NNP Biotech_NNP ,_,
          Uppsala_NNP ,_, Sweden_NNP )_) ._. The_DT following_VBG monoclonal_NN antibody_NN
          combinations_NNS were_VBD used_VBN to_TO characterize_VB the_DT phenotypes_NNS of_IN
          T_NN cells_NNS :_:
          anti-_NN CD_NNP 45_CD RA-FITC_NNP /_NN anti-_NN CD_NNP 3_CD -_: PE_NNP /_NN anti-_NN CD_NNP 62_CD L-C_NNP yChrome_NN /_NN
          anti-_NN CD_NNP 4_CD -_: APC_NNP ;_: and_CC
          anti-_NN CD_NNP 45_CD RA-FITC_NNP /_NN anti-_NN CD_NNP 3_CD -_: PE_NNP /_NN anti-_NN CD_NNP 62_CD L-C_NNP yChrome_NN /_NN anti-_NN CD_NNP 8_CD -_: APC_NNP
          (_( PharMingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Briefly_NNP ,_, 10_CD 6_CD peripheral_JJ
          blood_NN mononuclear_NN cells_NNS were_VBD stained_JJ with_IN each_DT
          combination_NN of_IN antibodies_NNS in_IN Hanks_NNP buffered_JJ saline_NN
          solution_NN (_( Cellgro_NNP ,_, Herndon_NNP ,_, VA_NNP ,_, USA_NNP )_) ,_, 3_CD %_NN fetal_JJ bovine_JJ
          serum_NN ,_, and_CC 0_CD ._. 02_CD %_NN NaN_NNP 
          3_CD for_IN 15_CD min_NN on_IN ice_NN ;_: washed_VBN twice_RB with_IN
          Hanks_NNP buffered_JJ saline_NN solution_NN ,_, 3_CD %_NN fetal_JJ bovine_JJ serum_NN and_CC
          0_CD ._. 02_CD %_NN NaN_NNP 
          3_CD ;_: and_CC fixed_VBN with_IN 1_CD %_NN
          paraformaldehyde_NN ._. Analysis_NNP was_VBD performed_VBN on_IN a_DT
          FACS-Calibur_NNP (_( Becton_NNP Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP ,_, USA_NNP )_) using_VBG
          FlowJo_NNP software_NN (_( TreeStar_NNP ,_, San_NNP Carlos_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP analysis_NN was_VBD performed_VBN using_VBG Mann-_NNP Whitney_NNP
          U_NNP test_NN ,_, Student_NNP 's_POS 
          t_NN -_: test_NN ,_, linear_JJ regression_NN ,_, and_CC
          Shapiro-_NNP Wilk_NNP W_NNP test_NN for_IN normality_NN ._. 
          P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          statistically_RB significant_JJ ._. The_DT JMP_NNP statistical_JJ analysis_NN
          program_NN was_VBD used_VBN (_( SAS_NNP ,_, Cary_NNP ,_, NC_NNP ,_, USA_NNP )_) ._.
        
      
      
        Results_NNS
        Naïve_NNP and_CC memory_NN subpopulations_NNS of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS
        from_IN RA_NNP and_CC SLE_NNP patients_NNS were_VBD compared_VBN with_IN those_DT in_IN
        healthy_JJ control_NN individuals_NNS to_TO determine_VB T-_NNP cell_NN maturation_NN
        differences_NNS between_IN those_DT groups_NNS ._.
        As_IN compared_VBN with_IN the_DT healthy_JJ control_NN group_NN ,_, RA_NNP patients_NNS
        had_VBD fewer_JJR CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP +_NN CD_NNP 4_CD +_NN naïve_NN T_NN cells_NNS (_( 32_CD ±_NN 4_CD ._. 8_CD %_NN in_IN
        RA_NNP patients_NNS [_NN 
        n_NN =_SYM 8_CD ]_NN and_CC 42_CD ±_NN 6_CD ._. 5_CD %_NN in_IN healthy_JJ
        controls_NNS [_NN 
        n_NN =_SYM 8_CD ]_NN ,_, respectively_RB )_) ,_, although_IN this_DT
        difference_NN was_VBD not_RB statistically_RB significant_JJ (_( Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._.
        The_DT CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP +_NN CD_NNP 4_CD +_NN central_JJ memory_NN T-_NNP cell_NN population_NN
        was_VBD significantly_RB increased_VBN in_IN RA_NNP patients_NNS (_( 50_CD ±_NN 3_CD ._. 7_CD %_NN [_NN 
        n_NN =_SYM 8_CD ]_NN )_) as_IN compared_VBN with_IN the_DT healthy_JJ
        control_NN group_NN (_( 38_CD ±_NN 4_CD ._. 4_CD %_NN [_NN 
        n_NN =_SYM 8_CD ]_NN ;_: 
        P_NN <_NN 0_CD ._. 05_CD ;_: Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._. No_DT
        differences_NNS were_VBD found_VBN in_IN the_DT CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP -_: CD_NNP 4_CD +_NN effector_NN
        memory_NN population_NN (_( 15_CD ±_NN 2_CD ._. 2_CD %_NN for_IN RA_NNP patients_NNS and_CC 18_CD ±_NN 2_CD ._. 6_CD %_NN
        for_IN healthy_JJ controls_NNS [_NN 
        n_NN =_SYM 8_CD each_DT ]_NN )_) or_CC in_IN the_DT terminally_RB
        differentiated_JJ CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: CD_NNP 4_CD +_NN effector_NN memory_NN
        population_NN (_( 1_CD ._. 7_CD ±_NN 0_CD ._. 5_CD %_NN for_IN RA_NNP patients_NNS and_CC 2_CD ._. 2_CD ±_NN 0_CD ._. 6_CD %_NN for_IN
        healthy_JJ controls_NNS [_NN 
        n_NN =_SYM 8_CD each_DT ]_NN ;_: Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._.
        In_IN the_DT CD_NNP 8_CD +_NN T-_NNP cell_NN population_NN ,_, 39_CD ±_NN 6_CD ._. 2_CD %_NN were_VBD CD_NNP 45_CD RA_NNP
        +_NN CD_NNP 62_CD L_NNP +_NN naïve_NN cells_NNS for_IN the_DT RA_NNP patients_NNS and_CC 28_CD ±_NN 3_CD ._. 4_CD %_NN for_IN
        the_DT healthy_JJ control_NN group_NN (_( Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._. The_DT central_JJ memory_NN
        CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP +_NN CD_NNP 8_CD +_NN T-_NNP cell_NN population_NN was_VBD significantly_RB
        increased_VBN in_IN RA_NNP patients_NNS (_( 17_CD ±_NN 3_CD ._. 5_CD %_NN [_NN 
        n_NN =_SYM 8_CD ]_NN )_) as_IN compared_VBN with_IN the_DT healthy_JJ
        control_NN group_NN (_( 9_CD ±_NN 1_CD ._. 8_CD %_NN [_NN 
        n_NN =_SYM 8_CD ]_NN ;_: 
        P_NN <_NN 0_CD ._. 05_CD ;_: Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._. No_DT
        difference_NN was_VBD found_VBN between_IN patients_NNS and_CC healthy_JJ control_NN
        group_NN in_IN the_DT CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP -_: CD_NNP 8_CD +_NN effector_NN memory_NN
        populations_NNS (_( 18_CD ±_NN 3_CD ._. 2_CD %_NN for_IN RA_NNP patients_NNS and_CC 25_CD ±_NN 4_CD ._. 5_CD %_NN for_IN
        healthy_JJ controls_NNS [_NN 
        n_NN =_SYM 8_CD ]_NN )_) ,_, whereas_IN the_DT CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP
        -_: CD_NNP 8_CD +_NN terminally_RB differentiated_JJ effector_NN memory_NN population_NN
        was_VBD significantly_RB decreased_VBN in_IN RA_NNP patients_NNS (_( 26_CD ±_NN 2_CD ._. 4_CD %_NN )_) as_IN
        compared_VBN with_IN healthy_JJ controls_NNS (_( 38_CD ±_NN 4_CD ._. 8_CD %_NN [_NN 
        n_NN =_SYM 8_CD ]_NN ;_: 
        P_NN <_NN 0_CD ._. 05_CD ;_: Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._.
        No_DT significant_JJ differences_NNS were_VBD found_VBN when_WRB CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD
        +_NN T_NN cells_NNS of_IN SLE_NNP patients_NNS were_VBD compared_VBN with_IN the_DT CD_NNP 4_CD +_NN and_CC
        CD_NNP 8_CD +_NN T_NN cells_NNS of_IN matched_VBN healthy_JJ control_NN individuals_NNS (_( Fig_NNP ._.
        1_LS c_SYM )_) ._. In_IN the_DT CD_NNP 4_CD +_NN T-_NNP cell_NN population_NN ,_, 35_CD ±_NN 4_CD ._. 6_CD %_NN of_IN cells_NNS from_IN
        SLE_NNP patients_NNS and_CC 45_CD ±_NN 4_CD ._. 7_CD %_NN in_IN the_DT healthy_JJ controls_NNS
        exhibited_VBN a_DT naïve_NN phenotype_NN ;_: the_DT central_JJ memory_NN phenotype_NN
        was_VBD expressed_VBN by_IN 42_CD ±_NN 3_CD ._. 8_CD %_NN of_IN the_DT CD_NNP 4_CD +_NN T_NN cells_NNS from_IN SLE_NNP
        patients_NNS (_( 
        n_NN =_SYM 12_CD )_) and_CC in_IN 37_CD ±_NN 3_CD ._. 1_CD %_NN of_IN the_DT CD_NNP 4_CD
        +_NN T_NN cells_NNS from_IN healthy_JJ controls_NNS (_( 
        n_NN =_SYM 12_CD )_) ._. Of_IN the_DT CD_NNP 4_CD +_NN T_NN cells_NNS ,_, 20_CD ±_NN
        3_CD ._. 6_CD %_NN and_CC 16_CD ±_NN 2_CD ._. 0_CD %_NN were_VBD effector_NN memory_NN cells_NNS in_IN the_DT SLE_NNP
        and_CC healthy_JJ control_NN groups_NNS (_( 
        n_NN =_SYM 12_CD in_IN each_DT )_) ,_, respectively_RB ,_, and_CC
        only_RB a_DT very_RB small_JJ population_NN of_IN the_DT cells_NNS were_VBD terminally_RB
        differentiated_JJ effector_NN memory_NN CD_NNP 4_CD +_NN T_NN cells_NNS in_IN SLE_NNP patients_NNS
        (_( 2_CD ._. 4_LS ±_NN 0_CD ._. 9_CD %_NN )_) and_CC healthy_JJ controls_NNS (_( 1_CD ._. 7_CD ±_NN 0_CD ._. 5_CD %_NN ;_: Fig_NNP ._. 1_LS c_SYM )_) ._.
        The_DT CD_NNP 8_CD +_NN T-_NNP cell_NN compartment_NN of_IN SLE_NNP patients_NNS consisted_VBD of_IN 42_CD
        ±_NN 5_CD ._. 6_CD %_NN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP +_NN naïve_NN cells_NNS ,_, 14_CD ±_NN 2_CD ._. 9_CD %_NN CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP
        +_NN central_JJ memory_NN ,_, 20_CD ±_NN 4_CD ._. 1_CD %_NN CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP -_: effector_NN memory_NN ,_,
        and_CC 24_CD ±_NN 4_CD ._. 9_CD %_NN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: terminally_RB differentiated_JJ
        effector_NN memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS (_( 
        n_NN =_SYM 12_CD ;_: Fig_NNP ._. 1_LS c_SYM )_) ._. In_IN the_DT healthy_JJ
        control_NN group_NN ,_, 39_CD ±_NN 5_CD ._. 8_CD %_NN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP +_NN naïve_NN cells_NNS ,_, 9_CD ±_NN
        1_CD ._. 3_CD %_NN CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP +_NN central_JJ memory_NN ,_, 23_CD ±_NN 3_CD ._. 4_CD %_NN CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP
        -_: effector_NN memory_NN ,_, and_CC 29_CD ±_NN 5_CD ._. 2_CD %_NN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: terminally_RB
        differentiated_JJ effector_NN memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS were_VBD found_VBN (_( 
        n_NN =_SYM 12_CD ;_: Fig_NNP ._. 1_LS c_SYM )_) ._.
        A_DT positive_JJ correlation_NN was_VBD found_VBN between_IN the_DT age_NN and_CC the_DT
        percentage_NN of_IN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: terminally_RB differentiated_JJ
        effector_NN memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN the_DT healthy_JJ control_NN group_NN (_(
        
        r_LS 2_CD =_SYM 0_CD ._. 64_CD [_NN 
        n_NN =_SYM 13_CD ]_NN ;_: 
        P_NN <_NN 0_CD ._. 001_CD ;_: Fig_NNP ._. 1_LS d_SYM )_) ,_, indicating_VBG
        that_IN this_DT effector_NN population_NN increases_NNS with_IN age_NN ._. However_RB ,_,
        no_DT such_JJ correlation_NN was_VBD detected_VBN in_IN RA_NNP and_CC SLE_NNP patients_NNS
        (_( Fig_NNP ._. 1_LS d_SYM )_) ._. Finally_RB ,_, the_DT frequency_NN of_IN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: CD_NNP 8_CD +_NN T_NN
        cells_NNS did_VBD not_RB correlate_VBP with_IN disease_NN duration_NN or_CC treatment_NN
        in_IN either_DT RA_NNP or_CC SLE_NNP patients_NNS (_( data_NNS not_RB shown_VBN )_) ._.
      
      
        Discussion_NNP
        The_DT present_JJ study_NN shows_VBZ that_IN the_DT differentiation_NN of_IN
        peripheral_JJ blood_NN CD_NNP 8_CD +_NN T_NN cells_NNS is_VBZ skewed_VBN in_IN patients_NNS with_IN RA_NNP
        and_CC results_NNS in_IN an_DT increase_NN in_IN central_JJ memory_NN CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP
        +_NN CD_NNP 8_CD +_NN T_NN cells_NNS ,_, with_IN a_DT concomitant_NN decrease_NN in_IN terminally_RB
        differentiated_JJ effector_NN memory_NN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: CD_NNP 8_CD +_NN T_NN cells_NNS ._.
        The_DT increase_NN in_IN central_JJ memory_NN CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP +_NN T_NN cells_NNS was_VBD
        also_RB found_VBN in_IN the_DT CD_NNP 4_CD +_NN T-_NNP cell_NN population_NN in_IN RA_NNP patients_NNS ._.
        This_DT skewed_VBN differentiation_NN was_VBD not_RB observed_VBN in_IN healthy_JJ
        age-matched_JJ control_NN individuals_NNS and_CC in_IN SLE_NNP patients_NNS ,_,
        indicating_VBG that_IN this_DT perturbation_NN in_IN homeostasis_NNS of_IN T_NN cells_NNS
        is_VBZ a_DT specific_JJ feature_NN of_IN RA_NNP ._.
        Although_IN the_DT naïve_NN /_NN memory_NN phenotype_NN of_IN T_NN cells_NNS has_VBZ
        previously_RB been_VBN investigated_VBN in_IN RA_NNP in_IN numerous_JJ studies_NNS
        using_VBG CD_NNP 45_CD RA_NNP and_CC CD_NNP 45_CD RO_NNP expression_NN as_IN markers_NNS of_IN naïve_NN and_CC
        memory_NN cells_NNS ,_, respectively_RB ,_, that_DT approach_NN has_VBZ suffered_VBN from_IN
        the_DT limitation_NN that_IN large_JJ numbers_NNS of_IN CD_NNP 45_CD RA_NNP +_NN CD_NNP 8_CD +_NN T_NN cells_NNS
        are_VBP actually_RB effector_NN memory_NN cells_NNS [_NN 10_CD 13_CD ]_NN ._. The_DT
        CD_NNP 45_CD RA_NNP /_NN CD_NNP 45_CD RO_NNP oversimplification_NN has_VBZ also_RB resulted_VBN in_IN
        rather_RB confusing_JJ conclusions_NNS regarding_VBG T-_NNP cell_NN homeostasis_NNS ,_,
        such_JJ as_IN defects_NNS in_IN primary_JJ T-_NNP cell_NN homeostasis_NNS based_VBN on_IN
        reduced_VBN T-_NNP cell_NN receptor_NN excision_NN circle_NN (_( TREC_NNP )_) levels_NNS in_IN
        naïve_NN CD_NNP 4_CD +_NN T_NN cells_NNS (_( defined_VBN as_IN CD_NNP 45_CD RO_NNP -_: )_) in_IN RA_NNP patients_NNS [_NN
        14_CD ]_NN ._. Our_PRP$ findings_NNS suggest_VBP that_WDT reduced_VBD TREC_NNP levels_NNS in_IN the_DT
        CD_NNP 45_CD RO_NNP -_: CD_NNP 4_CD +_NN T-_NNP cell_NN population_NN may_MD not_RB be_VB due_JJ to_TO a_DT
        reduction_NN in_IN TRECs_NNP in_IN naïve_NN cells_NNS but_CC rather_RB to_TO reduced_VBN
        TRECs_NNP in_IN the_DT CD_NNP 45_CD RA_NNP +_NN CD_NNP 45_CD RO_NNP -_: CD_NNP 62_CD L_NNP -_: effector_NN memory_NN CD_NNP 4_CD +_NN T_NN
        cells_NNS ._. It_PRP should_MD be_VB noted_VBN that_IN previous_JJ studies_NNS have_VBP
        reported_VBN '_POS false_JJ naïve_NN '_'' CD_NNP 45_CD RA_NNP +_NN populations_NNS of_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD
        +_NN T_NN cells_NNS in_IN peripheral_JJ blood_NN of_IN RA_NNP patients_NNS [_NN 15_CD ]_NN ;_:
        however_RB ,_, the_DT nature_NN of_IN these_DT cells_NNS ,_, the_DT exact_JJ phenotype_NN ,_,
        and_CC the_DT significance_NN was_VBD not_RB known_VBN at_IN that_DT time_NN ._.
        Our_PRP$ finding_VBG that_IN peripheral_JJ blood_NN CD_NNP 8_CD +_NN T_NN cells_NNS exhibit_NN
        increased_VBD central_JJ memory_NN phenotype_NN and_CC decreased_VBD terminally_RB
        differentiated_JJ effector_NN memory_NN phenotype_NN suggests_VBZ that_IN the_DT
        peripheral_JJ blood_NN homeostasis_NNS of_IN CD_NNP 8_CD +_NN T_NN cells_NNS is_VBZ perturbed_VBD
        in_IN RA_NNP ._. Perturbations_NNP in_IN CD_NNP 8_CD +_NN T-_NNP cell_NN maturation_NN have_VBP been_VBN
        shown_VBN for_IN HIV-specific_NNP CD_NNP 8_CD +_NN T_NN cells_NNS ,_, in_IN which_WDT there_EX is_VBZ an_DT
        accumulation_NN of_IN preterminally_RB differentiated_JJ CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP
        -_: CD_NNP 8_CD +_NN T_NN cells_NNS [_NN 12_CD 16_CD ]_NN ,_, and_CC such_JJ a_DT lack_NN of_IN
        differentiation_NN may_MD result_VB in_IN functional_JJ or_CC homing_VBG defects_NNS ._.
        In_IN RA_NNP we_PRP found_VBD a_DT decrease_NN in_IN terminally_RB differentiated_JJ
        CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: CD_NNP 8_CD +_NN T_NN cells_NNS with_IN a_DT concomitant_NN increase_NN in_IN
        the_DT CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP +_NN central_JJ memory_NN population_NN ._. If_IN one_CD
        accepts_VBZ the_DT linear_JJ model_NN of_IN differentiation_NN [_NN 10_CD ]_NN ,_, which_WDT
        we_PRP note_VBP has_VBZ been_VBN challenged_VBN [_NN 12_CD ]_NN ,_, then_RB our_PRP$ findings_NNS
        indicate_VBP that_IN in_IN RA_NNP there_EX may_MD be_VB an_DT accelerated_VBN
        differentiation_NN of_IN naïve_NN cells_NNS into_IN central_JJ memory_NN CD_NNP 4_CD +_NN and_CC
        CD_NNP 8_CD +_NN T_NN cells_NNS ._. This_DT accelerated_VBN differentiation_NN may_MD be_VB due_JJ
        to_TO a_DT non-antigen-specific_JJ effect_NN in_IN RA_NNP that_IN differentiates_NNS
        all_DT peripheral_JJ T_NN cells_NNS irrespective_RB of_IN their_PRP$ specificity_NN ,_,
        or_CC it_PRP may_MD actually_RB reflect_VB an_DT antigen-specific_JJ expansion_NN of_IN
        T_NN cells_NNS potentially_RB driven_VBN by_IN autoantigen_NN ._.
        The_DT decrease_NN in_IN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: effector_NN memory_NN CD_NNP 8_CD +_NN T_NN
        cells_NNS in_IN peripheral_JJ blood_NN we_PRP found_VBD in_IN RA_NNP patients_NNS may_MD
        reflect_VB a_DT decrease_NN in_IN the_DT survival_NN of_IN these_DT cells_NNS ._. It_PRP
        should_MD be_VB noted_VBN ,_, however_RB ,_, that_IN peripheral_JJ blood_NN T_NN cells_NNS
        from_IN RA_NNP patients_NNS do_VBP not_RB exhibit_VB an_DT increase_NN in_IN apoptosis_NNS in_IN
        
        in_IN vitro_NN cultures_NNS ,_, which_WDT is_VBZ in_IN
        contrast_NN to_TO synovial_NN membrane_NN T_NN cells_NNS [_NN 17_CD 18_CD ]_NN ._. This_DT may_MD
        suggest_VB that_IN the_DT skewed_VBN phenotype_NN of_IN the_DT CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP
        -_: effector_NN memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS is_VBZ more_RBR likely_JJ due_NN to_TO an_DT
        increase_NN in_IN the_DT migration_NN of_IN these_DT cells_NNS into_IN sites_NNS of_IN
        inflammation_NN ._. However_RB ,_, a_DT blockade_NN of_IN the_DT differentiation_NN of_IN
        central_JJ memory_NN CD_NNP 45_CD RA_NNP -_: CD_NNP 62_CD L_NNP +_NN CD_NNP 8_CD +_NN T_NN cells_NNS into_IN effector_NN
        memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS would_MD also_RB result_VB in_IN an_DT increase_NN in_IN the_DT
        central_JJ memory_NN population_NN with_IN a_DT concomitant_NN decrease_NN in_IN
        the_DT effector_NN T_NN cells_NNS ,_, as_IN observed_VBN in_IN the_DT present_JJ study_NN ._.
        Studies_NNS of_IN the_DT phenotype_NN of_IN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN the_DT synovial_NN
        membrane_NN and_CC fluid_NN may_MD shed_VB light_JJ as_IN to_TO whether_IN this_DT skewed_JJ
        phenotype_NN is_VBZ also_RB found_VBN in_IN these_DT sites_NNS or_CC whether_IN there_EX is_VBZ
        an_DT enrichment_NN for_IN CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP -_: CD_NNP 8_CD +_NN T_NN cells_NNS ,_, indicating_VBG
        increased_VBN recruitment_NN into_IN the_DT inflamed_JJ synovium_NN in_IN RA_NNP ._.
        Inflammation_NNP and_CC production_NN of_IN chemokines_NNS such_JJ as_IN
        macrophage_NN inflammatory_JJ protein-_NN 1_CD α_NN and_CC RANTES_NNP [_NN 7_CD 8_CD ]_NN in_IN
        the_DT synovium_NN may_MD result_VB in_IN preferential_JJ recruitment_NN of_IN such_JJ
        effector_NN memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS (_( which_WDT are_VBP important_JJ
        contributors_NNS to_TO IFN-γ_NNP production_NN )_) and_CC subsequent_JJ macrophage_NN
        activation_NN ,_, because_IN terminally_RB differentiated_JJ CD_NNP 45_CD RA_NNP +_NN CD_NNP 62_CD L_NNP
        -_: CD_NNP 8_CD +_NN T_NN cells_NNS have_VBP been_VBN shown_VBN to_TO express_VB higher_JJR levels_NNS of_IN
        perforin_NN and_CC may_MD be_VB more_RBR potent_JJ effector_NN cells_NNS [_NN 10_CD ]_NN ._. The_DT
        question_NN arises_VBZ of_IN whether_IN the_DT observed_VBN skewed_VBN
        differentiation_NN of_IN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN RA_NNP patients_NNS is_VBZ due_JJ to_TO
        medication_NN ,_, especially_RB steroids_NNS ._. As_IN shown_VBN in_IN Table_NNP 1_CD ,_, 38_CD %_NN
        of_IN the_DT RA_NNP patients_NNS and_CC 58_CD %_NN of_IN the_DT SLE_NNP patients_NNS were_VBD
        receiving_VBG steroid_NN treatment_NN ._. However_RB ,_, the_DT skewed_VBN memory_NN
        phenotype_NN was_VBD only_RB observed_VBN in_IN the_DT RA_NNP patients_NNS ,_, suggesting_VBG
        that_IN this_DT treatment_NN is_VBZ not_RB responsible_JJ for_IN the_DT differences_NNS
        in_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T-_NNP cell_NN phenotypes_NNS ._.
        Findings_NNP from_IN the_DT present_JJ preliminary_JJ study_NN show_NN that_IN
        peripheral_JJ blood_NN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN RA_NNP exhibit_NN a_DT skewed_VBN
        effector_NN memory_NN phenotype_NN ._. This_DT skewed_VBN phenotype_NN was_VBD not_RB
        found_VBN in_IN CD_NNP 4_CD +_NN T_NN cells_NNS in_IN RA_NNP and_CC was_VBD not_RB seen_VBN in_IN age-matched_JJ
        healthy_JJ control_NN individuals_NNS or_CC in_IN SLE_NNP patients_NNS ._. The_DT skewed_VBN
        phenotype_NN may_MD be_VB a_DT result_NN of_IN accelerated_JJ differentiation_NN
        and_CC migration_NN into_IN sites_NNS of_IN inflammation_NN ._. An_DT understanding_NN
        of_IN the_DT mechanisms_NNS that_WDT are_VBP involved_VBN in_IN this_DT skewed_JJ
        differentiation_NN of_IN effector_NN memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS may_MD prove_VB
        valuable_JJ in_IN elucidating_VBG the_DT pathogenesis_NNS of_IN RA_NNP ._.
      
      
        Conclusion_NNP
        In_IN peripheral_JJ blood_NN of_IN RA_NNP patients_NNS a_DT skewed_VBN homeostasis_NNS
        of_IN CD_NNP 8_CD +_NN T_NN cells_NNS was_VBD found_VBN ,_, with_IN an_DT increase_NN in_IN central_JJ
        memory_NN and_CC a_DT decrease_NN in_IN terminally_RB differentiated_JJ effector_NN
        memory_NN T_NN cells_NNS (_( Fig_NNP ._. 2_LS )_) ._. This_DT skewed_VBN T-_NNP cell_NN phenotype_NN was_VBD
        not_RB found_VBN in_IN healthy_JJ age-_NN and_CC sex-matched_JJ control_NN
        individuals_NNS or_CC in_IN patients_NNS with_IN SLE_NNP ._. Reduction_NNP in_IN
        peripheral_JJ blood_NN effector_NN memory_NN CD_NNP 8_CD +_NN T_NN cells_NNS in_IN RA_NNP may_MD
        indicate_VB an_DT increase_NN in_IN the_DT migration_NN of_IN these_DT cells_NNS into_IN
        sites_NNS of_IN inflammation_NN ,_, and_CC therefore_RB may_MD contribute_VB to_TO
        ongoing_JJ synovial_NN inflammation_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        IFN_NNP =_SYM interferon_NN ;_: IL_NNP =_SYM interleukin_NN ;_: RA_NNP =_SYM rheumatoid_NN
        arthritis_NN ;_: RANTES_NNP =_SYM regulated_VBN upon_IN activation_NN ,_, normal_JJ
        T-_NNP cell_NN expressed_VBD and_CC secreted_JJ ;_: SLE_NNP =_SYM systemic_JJ lupus_JJ
        erythematosus_JJ ;_: TREC_NNP =_SYM T-_NNP cell_NN receptor_NN excision_NN circle_NN ._.
      
    
  
